

Submission

[Home > Submission](#)

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/10/2015
Deadline Date	30/10/2015
Date Submitted	27/10/2015
Type	Historic Performance In Delivering
NHS provider	Maidstone and Tunbridge Wells NHS Trust

Showing records 1 to 8 of 8.

Pages: 1

Id	Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comment
66025	14/L/O/1476	McCave Roche Trial BP29262 - ca Phase 11, Multicenter, Randomized, Double-Blind Study To Evaluate The efficacy And Safety of R05520985 Plus Folfex Versus Bevacizumab Plus Folfex In Patients With Previously Untreated Metastatic Colorectal Cancer.	Available	5	Available	01/10/2015	Closed - In Follow Up	Y	
66026	14/NW/1258	ARAMS 3104007 ORION - A multicentre, randomised, double-blind, placebo-controlled, phase 111 efficacy and safety study of ODM-201 in men with high risk non-metastatic castration-resistant prostate cancer.	Available	4	No Date Agreed With Sponsor		Open	N/A	
66027	13/L/O/1557	CALM-NET: A Phase 4, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep S	Available	2	Available	30/11/2015	Open	N/A	
66028	14/Y/H/1237	FLAURA-1 - A phase 111, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Recep	Available	15	Available	31/03/2016	Open	N/A	
66029	15/L/O/0016	MONARCH 3: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Lo	Available	3	Available	30/11/2015	Closed - In Follow Up	N/A	
66030	13/EM/0348	Monoprost compared with Lumigan in POA glaucoma/ocular hypertension	Available	10	No Date Agreed With Sponsor		Open	N/A	
66031	14/NW/1052	B5371002: A Phase 3 Randomised, Double-Blind Study assessing the efficacy and safety of PF-06438179 and Infliximab in combination with Methotrexate in subjects with moderately to severely active Rheumatoid Arthritis who have had an inadequate response to	Available	8	Available	12/01/2016	Open	N/A	
66037	15/L/O/0691	BMS-936558 A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)	Available	36	No Date Agreed With Sponsor		Open	N/A	

Showing records 1 to 8 of 8.

Pages: 1

[< Back](#)